![Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available](https://oncodaily.com/pub/uploads/2023/08/Earle-Burgess-1-e1706723177147-1280x1028.jpg)
Photo from Earle Burgess/LinkedIn
Jan 31, 2024, 17:49
Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available
Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn:
“Enfortumab vedotin is a blockbuster drug in bladder cancer.
Looks like it might have activity in prostate cancer as well.
Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available.
Large unmet need in this setting, so this could be a big deal if confirmed.”
Read Further.
Source: Earle Burgess/LinkedIn